-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Myasthenia gravis (MG), the most common disorder of the neuromuscular junction (NMJ), is caused by autoantibodies that impair neuromuscular transmission and cause voluntary muscle fatigue and weaknes.
This improves the diagnostic yield of patients with seronegative MG (SNMG), especially in pediatric and ophthalmic case.
Earliest serum samples from each SNMG patient and 50 healthy controls and 60 disease controls (aquaporin-positive neuromyelitis optica, multiple sclerosis, immune-mediated peripheral neuropathy, amyotrophic lateral sclerosis, myopathy) by l - Research on CBA.
Of the 82 patients with SNMG, 53 (72%) had systemic disease and 29 (28%) had ocular diseas.
Clinical characteristics and cell-based analysis (CBA) results of the SNMG cohort
Despite advances in MG antibody testing, radioimmunoassay for AChR or muscle-specific kinase antibodies remains negative in approximately 10% of patient.
Results of single and combined adult AChR/muscle-specific kinase antibody assays
The lack of LRP4 antibodies in the population is not entirely unexpecte.
About one-third of SNMG patients had AChR or muscle-specific kinase antibodies detected by l-CBA and effectively detected by combination l-CB.
